Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | +5.36% | +1.14% | +22.92% |
Apr. 23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
Apr. 10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Financials (USD)
Sales 2024 * | 72K | Sales 2025 * | 72K | Capitalization | 4.78M |
---|---|---|---|---|---|
Net income 2024 * | -4M | Net income 2025 * | -8M | EV / Sales 2024 * | 66.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 66.4 x |
P/E ratio 2024 * |
-3
x | P/E ratio 2025 * |
-2.4
x | Employees | 3 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.01% |
1 week | -4.00% | ||
Current month | -8.58% | ||
1 month | -11.58% | ||
3 months | +5.00% | ||
6 months | +24.91% | ||
Current year | +16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 22-09-26 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Wayne Linsley
BRD | Director/Board Member | 67 | 20-01-15 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 1.77 | +5.36% | 3 656 |
24-05-10 | 1.68 | -4.55% | 16,825 |
24-05-09 | 1.76 | -2.22% | 3,783 |
24-05-08 | 1.8 | +5.26% | 6,915 |
24-05-07 | 1.71 | -2.29% | 12,090 |
Delayed Quote Nasdaq, May 13, 2024 at 09:30 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.67% | 4.78M | |
-2.35% | 89.08B | |
+3.55% | 40.9B | |
-14.30% | 32.25B | |
+53.61% | 25.14B | |
-15.74% | 15.39B | |
-9.08% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+6.37% | 9.03B |
- Stock Market
- Equities
- SILO Stock